Combined Delivery of Paclitaxel and Tanespimycin via Micellar Nanocarriers: Pharmacokinetics, Efficacy and Metabolomic Analysis

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Katragadda, Usha ^a   Fan, Wei ^a   Wang, Yingzhe ^a   Teng, Quincy ^b   Tan, Chalet ^a  

^a MERCER UNIVERSITY   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; ALANINE; ASPARTIC ACID; CHOLINE; CREATINE; GLUCOSE; GLUTAMIC ACID; GLUTAMINE; LACTIC ACID; PACLITAXEL; TANESPIMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IN VIVO STUDY; LACTATE BLOOD LEVEL; METABOLOMICS; MICELLE; MOUSE; NONHUMAN; OVARY TUMOR; PROTON NUCLEAR MAGNETIC RESONANCE; TUMOR GROWTH; TUMOR XENOGRAFT; WHOLE BODY IMAGING;

ANIMALS; BENZOQUINONES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; HUMANS; LACTAMS, MACROCYCLIC; METABOLOME; METABOLOMICS; MICE; MICELLES; NANOPARTICLES; OVARIAN NEOPLASMS; PACLITAXEL; SPECTROSCOPY, NEAR-INFRARED; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874736925     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058619     Document Type: Article

References (30)

1. Davis ME, Chen Z, Shin DM, (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7: 771-782.
2. Matsumura Y, Maeda H, (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res 46: 6387-6392.
3. Aryal S, Hu C-MJ, Zhang L, (2010) Combinatorial drug conjugation enables nanoparticle dual drug delivery. Small 6: 1442-1448.
4. Dicko A, Mayer LD, Tardi PG, (2010) Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo. Expert Opin Drug Deliv 7: 1329-1341.
5. Kolishetti N, Dhar S, Valencia PM, Lin LQ, Karnik R, et al. (2010) Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. PNAS 107: 17939-17944.
6. Shin HC, Alani AWG, Rao DA, Rockich NC, Kwon GS, (2009) Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. J Control Release 140: 294-300.
7. Neckers L, Workman P, (2012) Hsp90 molecular chaperon inhibitors: are we there yet? Clin Cancer Res 18: 64-76.
8. Ramalingan SS, Egorin MJ, Ramanathan RK, Remick SC, Sikorski RP, et al. (2008) A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clin Cancer Res 14: 3456-3461.
9. Katragadda U, Teng Q, Rayaprolu B, Chandran T, Tan C, (2011) Multi-drug delivery to tumor cells via micellar nanocarriers. Int J Pharm 419: 281-286.
10. Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, et al. (2001) Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice. Cancer Chemother Pharmacol 47: 291-302.
11. Teng Q, Ekman DR, Huang W, Collette TW, (2012) Push-through direct injection NMR: an optimized automation method applied to metabolomics. Analyst 137: 2226-2232.
12. Teng Q, Huang W, Collette TW, Ekman DR, Tan C, (2009) A direct cell quenching method for cell-culture based metabolomics. Metabolomics 5: 199-208.
13. Collette TW, Teng Q, Jensen KM, Kahl MD, Makynen EA, et al. (2010) Impacts of an anti-androgen and an androgen/anti-androgen mixture exposure on the metabolite profile of male fathead minnow urine. Environ Sci Technol 44: 6881-6886.
14. Spaareboom A, van Tellingen O, Nooijen WJ, Beijnen JH, (1996) Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56: 2112-2115.
15. Mordon S, Devoisselle JM, Soulie-Begu S, Desmettre T, (1998) Indocyanine green: physicochemical factors affecting its fluorescence in vivo. Microvasc Res 55: 146-152.
16. Wheeler HO, Cranston WI, Meltzer JI, (1958) Hepatic uptake and biliary excretion of indocyanine green in the dog. Proc Soc Exp Biol Med 99: 11-14.
17. Münster PN, Basso A, Solit D, Norton L, Rosen N, (2001) Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin Cancer Res 7: 2228-2236.
18. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N, (2003) Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to taxol. Cancer Res 63: 2139-2144.
19. Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, et al. (2008) Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 68: 589-596.
20. Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, et al. (2001) In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 72: 191-202.
21. Nishiyama N, Kataoka K, (2006) Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther 112: 630-648.
22. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, et al. (2004) Phase I and pharmacokinetic study of Genexol-PM, a Cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10: 3708-3716.
23. Chen H, Kim S, He W, Wang H, Low PS, et al. (2008) Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo forster resonance energy transfer imaging. Langmuir 24: 5213-5217.
24. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB, (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20.
25. Kroemer G, Pouyssegur J, (2008) Tumor cell metabolism: cancer's Achilles heel. Cancer Cell 13: 472-481.
26. Hsu PP, Sabatini DM, (2008) Cancer cell metabolism: Warburg and beyond. Cell 134: 703-707.
27. Ward PS, Thompson CB, (2012) Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21: 297-308.
28. Levine AJ, Puzio-Kuter AM, (2010) The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330: 1340-1344.
29. Glunde K, Bhujwalla ZM, Ronen SM, (2011) Choline metabolism in malignant transformation. Nat Rev Cancer 11: 835-848.
30. Tang N, Du G, Wang N, Liu C, Hang H, et al. (2007) Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J Natl Cancer Inst 99: 1004-1015.